Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corporate Development and Strategy
07 September 2021 - 10:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, announced the
appointment of Patrick J. Fowler as Senior Vice President,
Corporate Development and Strategy, effective today.
Mr. Fowler joins Vericel with over 15 years of business
development, strategy and commercial operations experience in the
biotech and medical technology industries. Most recently, Mr.
Fowler served as Head, North America Strategy, Operations & New
Product Development for Sanofi, formerly Genzyme Corporation.
During his tenure at Sanofi, he also served as Head, North America
Business Development, Specialty Care, as well as Head of Biosurgery
Business Development & Portfolio Strategy. Previously, Mr.
Fowler served in a number of corporate development roles at
Genzyme. Mr. Fowler earned a Bachelor of Science in Molecular
Genetics and Cell Biology from the University of Minnesota and an
M.B.A. from the University of Toronto.
“Patrick is a proven corporate development leader with a strong
track record of success in executing strategic transactions, as
well as developing and implementing corporate and business unit
strategies across a variety of therapeutic area franchises,” said
Nick Colangelo, President and Chief Executive Officer of Vericel.
“I am delighted that Patrick is joining the Vericel executive
leadership team at a time when his extensive transactional and
commercial experience will help drive continued strong growth for
the Company in the years ahead.”
“Vericel’s innovative and high-growth product portfolio, coupled
with its unique profitability profile, provides significant
strategic flexibility for the Company to continue to enhance its
portfolio through both lifecycle management initiatives and
potential business development opportunities,” said Mr. Fowler. “I
am excited to join Vericel and look forward to working with the
team to generate value for patients and shareholders through the
continued growth of the Company’s current franchises as well as
through potential new external opportunities.”
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company’s website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2021 Vericel
Corporation. All rights reserved.
Forward Looking StatementsThis press release
contains forward-looking statements. Forward-looking statements are
subject to risks and uncertainties such as those described
in Vericel’s periodic reports on file with the Securities
and Exchange Commission. Actual results may differ materially from
anticipated results.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024